Diabetes Medication Safety
-
{
- All
- News
-
New Diabetes Generic Drug Gets Approval In US Market: All About Dapagliflozin
- Wednesday April 8, 2026
- Health | Written by Shreya Goswami
Zydus Lifesciences has received USFDA approval for generic dapagliflozin tablets used to treat type 2 diabetes. Here's how the drug works, its benefits, and why it is important for blood sugar control and heart health.
-
www.ndtv.com
-
Berberine vs Metformin: Which Weight Loss Medication Is Actually Safer For Your Liver?
- Monday April 6, 2026
- Health | Written by Rupashi Chhabra
Berberine is a natural bioactive compound, while metformin is a synthetic weight loss medication that can have an individualised impact on your liver. Here is how each of them can impact liver health and why you need to consult a medical professional
-
www.ndtv.com
-
GLP-1 Drugs In India: How To Spot Fakes Before It's Too Late
- Monday March 30, 2026
- Health | Written by Sambhav Kumar
Counterfeit GLP-1 drugs like semaglutide are rising in India amid growing demand and multiple cheaper versions entering the market.
-
www.ndtv.com
-
Weight-loss Drugs Linked To Preterm Birth Risk In Women With Pre-Existing Diabetes
- Thursday March 19, 2026
- Written by Sambhav Kumar
The research analysed data from more than 750,000 pregnancies, making it one of the largest studies to examine this issue so far.
-
doctor.ndtv.com
-
Affordable Semaglutide Is Coming: Should You Be Worried About Drug Safety, Health Risks And Side Effects?
- Thursday March 19, 2026
- Health | Written by Sambhav Kumar
India's healthcare landscape will change as semaglutide patents expire in 2026, allowing over 50 generic versions to enter the market and improve access for diabetes and obesity treatment.
-
www.ndtv.com
-
India Cracks Down On Ads For Weight-Loss Drugs Like GLP-1 In New Advisory
- Wednesday March 11, 2026
- Health | Reported by Tanushka Dutta, Edited by Shreya Goswami
India's Health Ministry has warned pharmaceutical firms against promoting GLP-1 weight-loss drugs to the public. The CDSCO says direct or indirect advertising, including influencer campaigns, violates drug laws and could attract regulatory action.
-
www.ndtv.com
-
Novo Nordisk Sues Telehealth Company Over 'Knock-Off' Weight Loss Drugs, Flags Patient Safety Risks
- Monday February 9, 2026
- Health | Written by Tanushka Dutta
The lawsuit, filed in the US, alleges that Hims infringed Novo Nordisk's patent by mass marketing compounded semaglutide products that have not been cleared by the US Food and Drug Administration (FDA).
-
www.ndtv.com
-
Can Non-Diabetics Take Ozempic For Weight Loss? Doctor Answers
- Friday December 12, 2025
- Health | Written by Varsha Vats
Ozempic is the brand name for a medication called semaglutide, which is primarily used to manage type 2 diabetes. It belongs to a class of drugs known as GLP-1 receptor agonists
-
www.ndtv.com
-
New Diabetes Generic Drug Gets Approval In US Market: All About Dapagliflozin
- Wednesday April 8, 2026
- Health | Written by Shreya Goswami
Zydus Lifesciences has received USFDA approval for generic dapagliflozin tablets used to treat type 2 diabetes. Here's how the drug works, its benefits, and why it is important for blood sugar control and heart health.
-
www.ndtv.com
-
Berberine vs Metformin: Which Weight Loss Medication Is Actually Safer For Your Liver?
- Monday April 6, 2026
- Health | Written by Rupashi Chhabra
Berberine is a natural bioactive compound, while metformin is a synthetic weight loss medication that can have an individualised impact on your liver. Here is how each of them can impact liver health and why you need to consult a medical professional
-
www.ndtv.com
-
GLP-1 Drugs In India: How To Spot Fakes Before It's Too Late
- Monday March 30, 2026
- Health | Written by Sambhav Kumar
Counterfeit GLP-1 drugs like semaglutide are rising in India amid growing demand and multiple cheaper versions entering the market.
-
www.ndtv.com
-
Weight-loss Drugs Linked To Preterm Birth Risk In Women With Pre-Existing Diabetes
- Thursday March 19, 2026
- Written by Sambhav Kumar
The research analysed data from more than 750,000 pregnancies, making it one of the largest studies to examine this issue so far.
-
doctor.ndtv.com
-
Affordable Semaglutide Is Coming: Should You Be Worried About Drug Safety, Health Risks And Side Effects?
- Thursday March 19, 2026
- Health | Written by Sambhav Kumar
India's healthcare landscape will change as semaglutide patents expire in 2026, allowing over 50 generic versions to enter the market and improve access for diabetes and obesity treatment.
-
www.ndtv.com
-
India Cracks Down On Ads For Weight-Loss Drugs Like GLP-1 In New Advisory
- Wednesday March 11, 2026
- Health | Reported by Tanushka Dutta, Edited by Shreya Goswami
India's Health Ministry has warned pharmaceutical firms against promoting GLP-1 weight-loss drugs to the public. The CDSCO says direct or indirect advertising, including influencer campaigns, violates drug laws and could attract regulatory action.
-
www.ndtv.com
-
Novo Nordisk Sues Telehealth Company Over 'Knock-Off' Weight Loss Drugs, Flags Patient Safety Risks
- Monday February 9, 2026
- Health | Written by Tanushka Dutta
The lawsuit, filed in the US, alleges that Hims infringed Novo Nordisk's patent by mass marketing compounded semaglutide products that have not been cleared by the US Food and Drug Administration (FDA).
-
www.ndtv.com
-
Can Non-Diabetics Take Ozempic For Weight Loss? Doctor Answers
- Friday December 12, 2025
- Health | Written by Varsha Vats
Ozempic is the brand name for a medication called semaglutide, which is primarily used to manage type 2 diabetes. It belongs to a class of drugs known as GLP-1 receptor agonists
-
www.ndtv.com